These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38053196)

  • 1. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
    Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M;
    Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.
    Elia AE; Lalli S; Monsurrò MR; Sagnelli A; Taiello AC; Reggiori B; La Bella V; Tedeschi G; Albanese A
    Eur J Neurol; 2016 Jan; 23(1):45-52. PubMed ID: 25664595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol.
    Albanese A; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Rinaldi G; Vanacore N; Dickie B;
    Front Neurol; 2022; 13():1009113. PubMed ID: 36237618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
    BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
    Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
    Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
    BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
    Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
    Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
    Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
    Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
    Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
    Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
    Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol of RESCUE-ALS: A Phase 2,
    Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
    BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.
    Nam JY; Lee TY; Kim K; Chun S; Kim MS; Shin JH; Sung JJ; Kim BJ; Kim BJ; Oh KW; Kim KS; Kim SH
    Trials; 2022 May; 23(1):415. PubMed ID: 35585556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on treatment with Cerebrolysin improves clinical symptoms in patients with ALS: results from a prospective, single-center, placebo-controlled, randomized, double-blind, phase II study.
    Firstenfeld AJ; Listorti J; Jalaff N; Loaiza Orozco CP; Navarrete Gosdenovich F; Schurr T
    J Med Life; 2023 Dec; 16(12):1750-1755. PubMed ID: 38585517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.